| answer text |
<p>The 2016 United Nations political declaration on antimicrobial resistance (AMR)
acknowledged the importance of delinking the cost of investment in research and development
on AMR from the price and volume of sales to facilitate equitable and affordable access
to new products and encouraged governments to explore innovative approaches.</p><p>
</p><p>It is critical that the National Health Service makes the best use of its resources.
Any payment model must therefore be based on a robust evaluation of the value that
a new antimicrobial product brings to patients and the public as a whole. The assessment
of how much value a new antibiotic brings is highly complex and will vary considerably
from one product to another.</p><p> </p><p>In the United Kingdom, NHS England and
the National Institute for Health and Care Excellence (NICE) are leading work to test
innovative models that pay companies based primarily on a NICE led health technology
assessment of their value to the NHS as opposed to the volumes used. This has the
potential to both promote good antimicrobial stewardship and provide a much-needed
incentive for the development of new antimicrobial agents that will, over time, provide
value for the NHS.</p><p> </p><p>The test will be subject to robust evaluation before
considering any wider change to purchasing policy. The UK represents only a small
part of the global market for these drugs and we want to send a signal to the rest
of the world that there are workable models to achieve the right sort of incentives
for these vital medicines.</p>
|
|
